Outcomes in dark-zone DLBCL. Left panels show Kaplan-Meier curves indicating the survival probability across the GEP classification subgroups, including tables of numbers at risk. Right panels show forest plots indicating the unadjusted hazard ratio and 95% confidence interval of each dark-zone group relative to GCB-DLBCL. (A-B) Progression-free survival and (C-D) overall survival in the DLC cohort. (E-F) Overall survival in the HMDS cohort. (G-H) Progression-free survival and (I-J) overall survival in the REMoDL-B cohort. All survival analyses were performed in patients with de novo DLBCL treated with R-CHOP.

Outcomes in dark-zone DLBCL. Left panels show Kaplan-Meier curves indicating the survival probability across the GEP classification subgroups, including tables of numbers at risk. Right panels show forest plots indicating the unadjusted hazard ratio and 95% confidence interval of each dark-zone group relative to GCB-DLBCL. (A-B) Progression-free survival and (C-D) overall survival in the DLC cohort. (E-F) Overall survival in the HMDS cohort. (G-H) Progression-free survival and (I-J) overall survival in the REMoDL-B cohort. All survival analyses were performed in patients with de novo DLBCL treated with R-CHOP.

Close Modal

or Create an Account

Close Modal
Close Modal